<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733951</url>
  </required_header>
  <id_info>
    <org_study_id>KN046-CHN-001</org_study_id>
    <nct_id>NCT03733951</nct_id>
  </id_info>
  <brief_title>KN046 in Subjects With Advanced Solid Tumors and Lymphoma</brief_title>
  <official_title>An Open-Label, Multicenter, Dose-Escalation and Expansion Phase Ia/Ib Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KN046 Monotherapy in Subjects With Advanced Solid Tumors and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase Ia/Ib, open-label, multicenter, dose-escalation and expansion study to
      evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of KN046 in
      subjects with advanced solid tumors and lymphoma .
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In the dose escalation part, number of participants with dose limiting toxicity (DLT).</measure>
    <time_frame>During the first 4 weeks of treatment.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In the dose expansion part,Objective response rate (ORR).</measure>
    <time_frame>up to 2 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>In the dose expansion part, Duration of response (DoR).</measure>
    <time_frame>up to 2 years.</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">285</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>KN046</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN046</intervention_name>
    <description>Phase Ia：Intravenous (IV) infusions, 1,3 and 5 milligrams per kilogram (mg/kg) every 2 weeks.
Phase Ib：Intravenous (IV) infusions, 1 ,3 or 3, 5 milligrams per kilogram (mg/kg) every 2 weeks, the dose of phase Ib based on the result of phase Ia.</description>
    <arm_group_label>KN046</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed informed consent; willing and able to complete all required procedures of
             study.

          2. With advanced-stage or metastatic tumor (unresectable) and experienced progression
             since last anti-tumor treatment; standard therapy is not available or rejected.

          3. Subjects must have at least one measurable lesion in advanced solid tumors, at least
             one measurable or assessable lesion in NK/T cell lymphoma.

          4. ECOG performance status of 0 or 1.

          5. Subject must have adequate organ function.

          6. Female patients and males with partners of childbearing potential should be using
             highly effective contraceptive measures (failure rate of less than 1% per year).
             Contraception should be continued for a period of 24 weeks after dosing has been
             completed.

          7. Ability to comply with treatment, procedures and PK sample collection and the required
             study follow-up procedures.

        Exclusion Criteria:

          1. Known brain metastasis or other CNS metastasis that is either symptomatic or
             untreated.

          2. Is currently participating or has participated in a study of an investigational drug
             within 4 weeks prior to the first dose of trial treatment.

          3. Patients who have received immune checkpoint proteins/antibody/medicine (including
             PD-1, PD-L1, etc) for treatment.

          4. Has interstitial lung disease, or a history of pneumonitis that required oral or
             intravenous glucocorticoids to assist with management.

          5. Subjects with active autoimmune diseases or history of autoimmune diseases should be
             excluded.

          6. Active HBV or HCV infection.

          7. Known HIV infection or known history of acquired immune deficient syndrome (AIDS).

          8. Any unresolved CTCAE Grade ≥ 2 toxicities from prior anti-cancer therapy with the
             exception of vitiligo, alopecia.

          9. Patients who have serious hypersensitive reaction to monoclonal antibodies, and have
             history of uncontrolled allergic asthma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danming Zhu, PH.D.</last_name>
    <phone>013810749637</phone>
    <email>danmingzhu@alphamab.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang, M.D.</last_name>
      <email>zhangli6@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Li Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

